JP2017535548A5 - - Google Patents

Download PDF

Info

Publication number
JP2017535548A5
JP2017535548A5 JP2017525946A JP2017525946A JP2017535548A5 JP 2017535548 A5 JP2017535548 A5 JP 2017535548A5 JP 2017525946 A JP2017525946 A JP 2017525946A JP 2017525946 A JP2017525946 A JP 2017525946A JP 2017535548 A5 JP2017535548 A5 JP 2017535548A5
Authority
JP
Japan
Prior art keywords
cancer
patient
expression
level
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017525946A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017535548A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/059733 external-priority patent/WO2016077227A2/en
Publication of JP2017535548A publication Critical patent/JP2017535548A/ja
Publication of JP2017535548A5 publication Critical patent/JP2017535548A5/ja
Pending legal-status Critical Current

Links

JP2017525946A 2014-11-14 2015-11-09 Ｖｅｇｆアンタゴニストの応答の予測 Pending JP2017535548A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462079787P 2014-11-14 2014-11-14
US62/079,787 2014-11-14
PCT/US2015/059733 WO2016077227A2 (en) 2014-11-14 2015-11-09 Predicting response to a vegf antagonist

Publications (2)

Publication Number Publication Date
JP2017535548A JP2017535548A (ja) 2017-11-30
JP2017535548A5 true JP2017535548A5 (https=) 2018-12-20

Family

ID=54754748

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017525946A Pending JP2017535548A (ja) 2014-11-14 2015-11-09 Ｖｅｇｆアンタゴニストの応答の予測

Country Status (15)

Country Link
US (1) US20170226198A1 (https=)
EP (1) EP3218401B1 (https=)
JP (1) JP2017535548A (https=)
KR (1) KR20170082537A (https=)
CN (1) CN107106688A (https=)
AR (1) AR102647A1 (https=)
AU (1) AU2015346652A1 (https=)
BR (1) BR112017009633A2 (https=)
CA (1) CA2966216A1 (https=)
HK (1) HK1242996A1 (https=)
IL (1) IL251947A0 (https=)
MX (1) MX2017006201A (https=)
RU (1) RU2017120388A (https=)
SG (1) SG11201703744VA (https=)
WO (1) WO2016077227A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108753984B (zh) * 2018-08-28 2021-07-13 北京市神经外科研究所 预测或诊断脑恶性胶质瘤术后复发的生物标志物组合及其应用和试剂盒
US20230340605A1 (en) * 2020-02-04 2023-10-26 Oslo Universitetssykehus Hf Biomarkers predicting clinical response of a vegf-a inhibitory drug in cancer patients, method for their selection and use
WO2021182572A1 (ja) * 2020-03-12 2021-09-16 東レ株式会社 癌の治療及び／又は予防のための医薬品
EP4565240A1 (en) * 2022-08-05 2025-06-11 Geistlich Pharma AG Combination therapy for treating cancers

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2277542B1 (en) * 2001-06-01 2014-04-16 Cornell Research Foundation Inc. Modified antibodies to prostrate-specific membrane antigen and uses thereof
US20040191218A1 (en) * 2001-09-26 2004-09-30 Emlen James W Pharmaceutical compositions and methods for treating cancer
AU2004215133B2 (en) * 2003-02-27 2010-10-14 Yeda Research And Development Co. Ltd. Nucleic acid molecules, polypeptides, antibodies and compositions containing same useful for treating and detecting influenza virus infection
EP1753442A2 (en) * 2004-06-10 2007-02-21 Regeneron Pharmaceuticals, Inc. Method of administering and using vegf inhibitors for the treatment of human cancer
AR073231A1 (es) * 2008-08-29 2010-10-20 Genentech Inc Metodos diagnosticos y tratamientos para los tumores independientes del vegf (factor de crecimiento endotelial vascular)
AU2011208805A1 (en) * 2010-01-19 2012-06-21 F. Hoffman-La Roche Ag Tumor tissue based biomarkers for bevacizumab combination therapies
KR102104197B1 (ko) * 2010-02-23 2020-04-24 제넨테크, 인크. 난소암의 치료를 위한 항혈관신생 요법
EP2848939A1 (en) * 2010-07-19 2015-03-18 F. Hoffmann-La Roche AG Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
AU2011281706A1 (en) * 2010-07-19 2013-01-10 F. Hoffmann-La Roche Ag Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer
JP5963005B2 (ja) * 2010-07-19 2016-08-03 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 膵臓癌の治療のためのベバシズマブ組合せ療法のための血漿バイオマーカー
RU2013131168A (ru) * 2010-12-09 2015-01-20 Ф. Хоффманн-Ля Рош Аг Agtr1 в качестве маркера для комбинированных терапий с использованием бевацизумаба
WO2012118969A2 (en) * 2011-03-01 2012-09-07 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Method of selecting cancer patients for anti-angiogenesis therapy in combination with chemotherapy
KR20140094594A (ko) * 2011-12-05 2014-07-30 에프. 호프만-라 로슈 아게 유방암 치료를 위한 베바시주맙 병용 치료에 대한 혈장 바이오마커

Similar Documents

Publication Publication Date Title
Singh et al. TNBC: potential targeting of multiple receptors for a therapeutic breakthrough, nanomedicine, and immunotherapy
JP2018508183A5 (https=)
Clarke et al. Understanding and targeting resistance to anti-angiogenic therapies
Battaglin et al. The role of tumor angiogenesis as a therapeutic target in colorectal cancer
Alese et al. Update on emerging therapies for advanced colorectal cancer
Goldman et al. Phase 1 dose‐escalation trial evaluating the combination of the selective MET (mesenchymal‐epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib
Farley et al. Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study
Nikolaou et al. The role of neurotensin and its receptors in non-gastrointestinal cancers: A review
Lim et al. CDK4/6 inhibitors: promising opportunities beyond breast cancer
Sun et al. Gastric cancer: current and evolving treatment landscape
Ayyappan et al. Epidermal growth factor receptor (EGFR)-targeted therapies in esophagogastric cancer
Ferté et al. IGF-1R targeting increases the antitumor effects of DNA-damaging agents in SCLC model: an opportunity to increase the efficacy of standard therapy
Eng et al. A randomized, placebo‐controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild‐type KRAS who have received first‐line systemic therapy
Gilbert et al. A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma
RU2017125054A (ru) Композиции и способы лечения и диагностики резистентного к химиотерапии рака
Souglakos et al. Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC)
Basu et al. Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer
JP2015514113A (ja) 単一特異性および二重特異性抗ｉｇｆ−１ｒおよび抗ｅｒｂｂ３抗体の用法および用量
JP7579636B2 (ja) 膵がん治療のための組み合わせ治療薬
Li et al. Deguelin suppresses angiogenesis in human hepatocellular carcinoma by targeting HGF-c-Met pathway
Aprile et al. The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey
Jeong et al. Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer
Ahmed et al. The rise of the TROP2-targeting agents in NSCLC: new options on the horizon
Shimizu et al. Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer
JP2017535548A5 (https=)